A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
复制标题
DOI：
10.3233/jad-2010-100408
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Wadsworth TL
中科院分区：
文献类型：
--
作者：
Quinn JF;Harris CJ;Cobb KE;Domes C;Ralle M;Brewer G;Wadsworth TL
越来越多的证据表明金属在阿尔茨海默病的病理学中起着至关重要的作用。β淀粉样蛋白的聚集和神经毒性都依赖于铜的存在。本研究调查了铜络合药物四硫代钼酸盐在预防和治疗阿尔茨海默病Tg2576小鼠模型中减少β淀粉样蛋白病理和空间记忆障碍的能力。四硫代钼酸盐治疗在预防模式中降低了脑铜和β淀粉样蛋白水平，但在治疗模式中没有。我们的数据表明，如果在疾病过程的早期开始，控制性降低全身铜可能会达到抗淀粉样蛋白的作用。
There is increasing evidence for the crucial role of metals in the pathology of Alzheimer’s disease. Both the aggregation and neurotoxicity of beta amyloid are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce beta amyloid pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer’s disease. Tetrathiomolybdate treatment lowered brain copper and reduced beta amyloid levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process.